<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551496</url>
  </required_header>
  <id_info>
    <org_study_id>S2348</org_study_id>
    <nct_id>NCT03551496</nct_id>
  </id_info>
  <brief_title>The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia</brief_title>
  <acronym>SAVAL</acronym>
  <official_title>A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two phased global, prospective, multicenter clinical trial designed to demonstrate a superior&#xD;
      patency rate and acceptable safety in below the knee arteries with lesions treated with the&#xD;
      DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase A: A global, prospective, multicenter, 2:1 randomized trial evaluating the safety and&#xD;
      effectiveness of the DES BTK Vascular Stent System compared to standard percutaneous&#xD;
      transluminal angioplasty to treat infrapopliteal artery lesions in subjects with critical&#xD;
      limb ischemia(CLI). Phase A RCT will begin with one size of the device: 3.5 mm x 80 mm.&#xD;
&#xD;
      Phase B: A global, prospective, multicenter, non-randomized trial collecting additional&#xD;
      safety and effectiveness data for the DES BTK Vascular Stent System to treat infrapopliteal&#xD;
      artery lesions in subjects with CLI. Additional stent sizes will be added to the trial upon&#xD;
      regulatory approval.&#xD;
&#xD;
      Approximately 201 subjects will be randomized/enrolled to support a 2:1 randomization in the&#xD;
      phase A RCT. Approximately 100 additional subjects are expected to be enrolled in phase B&#xD;
      non-randomized which is structured as a single arm where the enrolled subjects are treated&#xD;
      with the DES BTK Vascular Stent System.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">January 29, 2029</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately 201 subjects will be randomized in a 2:1 fashion for phase A RCT. Randomizations will be stratified by investigational center and lesion length with 2 subjects receiving the DES BTK for every 1 subject receiving treatment with standard PTA. Approximately 100 additional subjects will be enrolled in non-randomized phase B where the enrolled subjects are treated with the DES BTK.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>A review of the wound assessment data will be completed by independent reviewer(s) who will be blinded to the randomized therapy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency to demonstrate that the 12-month primary patency for the DES BTK treatment group is superior to the PTA</measure>
    <time_frame>12 months</time_frame>
    <description>The primary effectiveness endpoint assesses primary patency using duplex ultrasound at 12 months post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint assesses major adverse events (MAE) at 12 months post-procedure</measure>
    <time_frame>12 months</time_frame>
    <description>The primary safety endpoint assesses major adverse events (MAE) at 12 months post-procedure.(MAE is defined as: above ankle amputation in index limb; major re-intervention; and perioperative (30 day) mortality</description>
  </primary_outcome>
  <other_outcome>
    <measure>Primary and assisted primary patency</measure>
    <time_frame>1,6,12, 24 and 36 months post procedure</time_frame>
    <description>Target lesion patency rate measured by duplex ultrasound.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically driven target lesion revascularization</measure>
    <time_frame>1, 3, 6, 12, 24 and 36 months post procedure</time_frame>
    <description>Clinically-driven target lesion revascularization is any surgical or percutaneous intervention to the target lesion after the index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Major amputation rates</measure>
    <time_frame>1, 3, 6, 12, 24,and 36 months post procedure</time_frame>
    <description>Rates of amputation of the lower limb at the ankle level or above</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject quality-of-life values by change in EQ-5D (EuroQol 5 dimension)</measure>
    <time_frame>1, 3, 6 and 12 months post procedure</time_frame>
    <description>The EQ-5D is a descriptive system of health-related quality-of-life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 5 responses. The responses record 5 levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension). The levels are assigned a numeric code 1-5 (eg, 1= no problems and 5= extreme problems). Sub-scores are not applicable.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject quality-of-life values by change in VascuQol</measure>
    <time_frame>1, 3, 6 and 12 months post procedure</time_frame>
    <description>The VascuQol is a 25 item questionnaire used to measure the quality-of-life in patients with lower limb ischemia. The tool is sub-divided into 5 domains: pain, symptoms, activities, social and emotional. Each domain is scored 1-7 = the total of domain item scores divided by the number of questions in the domain. The total VascuQol score is also scored 1-7 = the total of all the item scores divided by 25.Sub-scores are not applicable.</description>
  </other_outcome>
  <other_outcome>
    <measure>Wound Assessment</measure>
    <time_frame>1, 3, 6, 12, 24, and 36 months post procedure</time_frame>
    <description>Descriptive characteristics of wound healing will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>3, 6, 12, 24, and 36 months post procedure</time_frame>
    <description>Change in Rutherford classification as assessed by the investigator</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1, 3, 6, 12, 24, and 36 months post procedure</time_frame>
    <description>Adverse events (AEs) (to be classified as major, serious, non-serious, unanticipated, procedure-related and device-related)</description>
  </other_outcome>
  <other_outcome>
    <measure>30-day unplanned hospital readmission rate</measure>
    <time_frame>Up to 30 days post procedure</time_frame>
    <description>Hospitalizations related to Critical Limb Ischemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival rate at 4 years and 5 years post-procedure</measure>
    <time_frame>4 and 5 years post procedure</time_frame>
    <description>Telephone follow-up visit and/or medical chart review and/or publicly available records consultation for vital status</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemodynamic outcomes</measure>
    <time_frame>6 and 12 months post procedure</time_frame>
    <description>Changes in ABI and/or TBI</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">301</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>DES BTK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with DES BTK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with standard PTA</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Drug Eluting Stent - Below the Knee</intervention_name>
    <description>Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm</description>
    <arm_group_label>DES BTK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA Control Arm</intervention_name>
    <description>The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.</description>
    <arm_group_label>Conventional PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 18 years or older and has signed and dated the trial informed consent form&#xD;
             (ICF)&#xD;
&#xD;
          2. Subject is willing and able to comply with the trial testing, procedures and follow-up&#xD;
             schedule&#xD;
&#xD;
          3. Subject has chronic, symptomatic lower limb ischemia, determined by Rutherford&#xD;
             categories 4 or 5 in the target limb, with wound(s) confined to toes/forefoot&#xD;
&#xD;
          4. Subject is a male or non-pregnant female. If female of child-bearing potential, and if&#xD;
             sexually active must be using, or agree to use, a medically-acceptable method of birth&#xD;
             control as confirmed by the investigator&#xD;
&#xD;
        Intra-procedure Inclusion Criteria:&#xD;
&#xD;
          1. Stenotic, restenotic or occlusive target lesion(s) located in the tibioperoneal trunk,&#xD;
             anterior tibial, posterior tibial and/or peroneal artery(ies).&#xD;
&#xD;
          2. Target lesion(s) must be at least 4cm above the ankle joint&#xD;
&#xD;
          3. A single target lesion per vessel, in up to 2 vessels, in a single limb&#xD;
&#xD;
          4. Degree of stenosis ≥ 70% by visual angiographic assessment&#xD;
&#xD;
          5. Reference vessel diameter is between 2.5 - 3.25mm for phase A RCT&#xD;
&#xD;
          6. RVD is between 2.5 - 3.75mm for phase B non-randomized (Note: RVD is dependent on&#xD;
             stent size being used. Refer to DFU for specific requirements)&#xD;
&#xD;
          7. Total target lesion length (or series of lesion segments) to be treated is ≤ 70 mm for&#xD;
             phase A RCT prior to the data monitoring committee's approval for stent overlap.&#xD;
             (Note: Lesion segment(s) must be fully covered with one DES BTK stent, if randomized&#xD;
             to stent)&#xD;
&#xD;
          8. Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm&#xD;
             for phase A RCT after the data monitoring committee's approval for stent overlap&#xD;
             (Note: Lesion segment(s) must be fully covered with up to two DES BTK stents, if&#xD;
             randomized to stent)&#xD;
&#xD;
          9. Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm&#xD;
             for phase B non-randomized (Note: Lesion segment(s) must be fully covered with up to&#xD;
             two DES BTK stents)&#xD;
&#xD;
         10. Target vessel(s) reconstitute(s) at or above the stenting limit zone (4cm above the&#xD;
             ankle joint)&#xD;
&#xD;
         11. Target lesion(s) is located in an area that may be stented without blocking access to&#xD;
             patent main branches&#xD;
&#xD;
         12. Treatment of all above the knee inflow lesion(s) is successful prior to treatment of&#xD;
             the target lesion&#xD;
&#xD;
         13. Guidewire has successfully crossed the target lesion(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy ≤ 1year&#xD;
&#xD;
          2. Stroke ≤ 90 days prior to the procedure date&#xD;
&#xD;
          3. Prior or planned major amputation in the target limb&#xD;
&#xD;
          4. Previous surgery in the target vessel(s) (including prior ipsilateral crural bypass)&#xD;
&#xD;
          5. Previously implanted stent in the target vessel(s)&#xD;
&#xD;
          6. Failed PTA of target lesion/vessel ≤ 60 days prior to the procedure date&#xD;
&#xD;
          7. Renal failure as measured by a GFR ≤ 30ml/min per 1.73m2, measured ≤ 30 days prior to&#xD;
             the procedure date&#xD;
&#xD;
          8. Subject has a platelet count ≤ 50 or ≥ 600 X 103/µL ≤ 30 days prior to the procedure&#xD;
             date&#xD;
&#xD;
          9. NYHA class IV heart failure&#xD;
&#xD;
         10. Subject has symptomatic coronary artery disease (ie, unstable angina)&#xD;
&#xD;
         11. History of myocardial infarction or thrombolysis ≤ 90 days prior to the procedure date&#xD;
&#xD;
         12. Non-atherosclerotic disease resulting in occlusion (eg, embolism, Buerger's disease,&#xD;
             vasculitis)&#xD;
&#xD;
         13. Subject is currently taking Canagliflozin&#xD;
&#xD;
         14. Body Mass Index (BMI) &lt;18&#xD;
&#xD;
         15. Active septicemia or bacteremia&#xD;
&#xD;
         16. Coagulation disorder, including hypercoagulability&#xD;
&#xD;
         17. Contraindication to anticoagulation or antiplatelet therapy&#xD;
&#xD;
         18. Known allergies to stent or stent components&#xD;
&#xD;
         19. Known allergy to contrast media that cannot be adequately pre-medicated prior to the&#xD;
             interventional procedure&#xD;
&#xD;
         20. Known hypersensitivity to heparin&#xD;
&#xD;
         21. Subject is on a high dose of steroids or is on immunosuppressive therapy&#xD;
&#xD;
         22. Subject is currently participating, or plans to participate in, another&#xD;
             investigational trial that may confound the results of this trial (unless written&#xD;
             approval is received from the Boston Scientific study team)&#xD;
&#xD;
        Intra-procedure Exclusion Criteria&#xD;
&#xD;
          1. Angiographic evidence of intra-arterial acute/subacute thrombus or presence of&#xD;
             atheroembolism&#xD;
&#xD;
          2. Treatment required in &gt; 2 target vessels (Note: a target lesion originating in one&#xD;
             vessel and extending into another vessel is considered 1 target vessel)&#xD;
&#xD;
          3. Treatment requires the use of alternate therapy in the target vessel(s)/lesion(s),&#xD;
             (eg, atherectomy, cutting balloon, re-entry devices, laser, radiation therapy)&#xD;
&#xD;
          4. Aneurysm is present in the target vessel(s)&#xD;
&#xD;
          5. Extremely calcified lesions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Cardiac &amp; Vascular Centers for Amputation Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendrik van Overhagen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HAGA Ziekenhuis (HagaZiekenhuis van Den Haag)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Geraghty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masato Nakamura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Center - Division of Cardiovascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado VA</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Cardiology</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Bossier Medical Center - Grace Research, LLC</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South Clinical Research Corporation</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiac &amp; Vascular Centers for Amputation Prevention</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular Clinic</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute, PA</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amputation Prevention Center of North Carolina</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research and Innovation Institute - Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Consultants in Cardiovascular Diseases at St. Vincent Hospital</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16544</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson-Madison County General Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THR Presbyterian Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Genk (Ziekenhuis Oost-Limburg)</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent (Universitair Ziekenhuis Gent)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Bay Urayasu Ichikawa Medical Center</name>
      <address>
        <city>Urayasu-shi</city>
        <state>Chiba-ken</state>
        <zip>279-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital</name>
      <address>
        <city>Asahikawa-shi</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University, Medical Hospital</name>
      <address>
        <city>Bunkyō-Ku</city>
        <state>Tokyo</state>
        <zip>113-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HAGA Ziekenhuis (Haga Ziekenhuis van Den Haag)</name>
      <address>
        <city>Den Haag</city>
        <zip>2566</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <reference>
    <citation>Kolte D, Kennedy KF, Shishehbor MH, Abbott JD, Khera S, Soukas P, Mamdani ST, Hyder ON, Drachman DE, Aronow HD. Thirty-Day Readmissions After Endovascular or Surgical Therapy for Critical Limb Ischemia: Analysis of the 2013 to 2014 Nationwide Readmissions Databases. Circulation. 2017 Jul 11;136(2):167-176. doi: 10.1161/CIRCULATIONAHA.117.027625. Epub 2017 May 2.</citation>
    <PMID>28465288</PMID>
  </reference>
  <reference>
    <citation>Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, Nehler MR, Powell RJ, Sidawy AN. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009 Dec;50(6):1462-73.e1-3. doi: 10.1016/j.jvs.2009.09.044. Epub 2009 Nov 7. Review.</citation>
    <PMID>19897335</PMID>
  </reference>
  <reference>
    <citation>Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M, Krankenberg H, Baumgartner I, Siablis D, Lammer J, Van Ransbeeck M, Qureshi AC, Stoll HP; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012 Dec 4;60(22):2290-5. doi: 10.1016/j.jacc.2012.08.989.</citation>
    <PMID>23194941</PMID>
  </reference>
  <reference>
    <citation>Spreen MI, Martens JM, Hansen BE, Knippenberg B, Verhey E, van Dijk LC, de Vries JP, Vos JA, de Borst GJ, Vonken EJ, Wever JJ, Statius van Eps RG, Mali WP, van Overhagen H. Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial. Circ Cardiovasc Interv. 2016 Feb;9(2):e002376. doi: 10.1161/CIRCINTERVENTIONS.114.002376.</citation>
    <PMID>26861113</PMID>
  </reference>
  <reference>
    <citation>Kinlay S. Management of Critical Limb Ischemia. Circ Cardiovasc Interv. 2016 Feb;9(2):e001946. doi: 10.1161/CIRCINTERVENTIONS.115.001946.</citation>
    <PMID>26858079</PMID>
  </reference>
  <reference>
    <citation>Elsayed S, Clavijo LC. Critical limb ischemia. Cardiol Clin. 2015 Feb;33(1):37-47. doi: 10.1016/j.ccl.2014.09.008. Review.</citation>
    <PMID>25439329</PMID>
  </reference>
  <reference>
    <citation>Conte MS. Critical appraisal of surgical revascularization for critical limb ischemia. J Vasc Surg. 2013 Feb;57(2 Suppl):8S-13S. doi: 10.1016/j.jvs.2012.05.114. Review.</citation>
    <PMID>23336860</PMID>
  </reference>
  <reference>
    <citation>Gray BH, Diaz-Sandoval LJ, Dieter RS, Jaff MR, White CJ; Peripheral Vascular Disease Committee for the Society for Cardiovascular Angiography and Interventions. SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014 Oct 1;84(4):539-45. doi: 10.1002/ccd.25395. Epub 2014 Jul 18.</citation>
    <PMID>25045160</PMID>
  </reference>
  <reference>
    <citation>Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005 Dec 3;366(9501):1925-34.</citation>
    <PMID>16325694</PMID>
  </reference>
  <reference>
    <citation>Popplewell MA, Davies HOB, Narayanswami J, Renton M, Sharp A, Bate G, Patel S, Deeks J, Bradbury AW. A Comparison of Outcomes in Patients with Infrapopliteal Disease Randomised to Vein Bypass or Plain Balloon Angioplasty in the Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL) Trial. Eur J Vasc Endovasc Surg. 2017 Aug;54(2):195-201. doi: 10.1016/j.ejvs.2017.04.020. Epub 2017 Jun 8.</citation>
    <PMID>28602580</PMID>
  </reference>
  <reference>
    <citation>Sadaghianloo N, Jean-Baptiste E, Declemy S, Mousnier A, Brizzi S, Hassen-Khodja R. Percutaneous angioplasty of long tibial occlusions in critical limb ischemia. Ann Vasc Surg. 2013 Oct;27(7):894-903. doi: 10.1016/j.avsg.2013.02.008.</citation>
    <PMID>23993107</PMID>
  </reference>
  <reference>
    <citation>Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, Schmidt A, Tessarek J, Vinck E, Schwartz LB. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012 Feb;55(2):390-8. doi: 10.1016/j.jvs.2011.07.099. Epub 2011 Dec 14.</citation>
    <PMID>22169682</PMID>
  </reference>
  <reference>
    <citation>Spreen MI, Martens JM, Knippenberg B, van Dijk LC, de Vries JPM, Vos JA, de Borst GJ, Vonken EPA, Bijlstra OD, Wever JJ, Statius van Eps RG, Mali WPTM, van Overhagen H. Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia. J Am Heart Assoc. 2017 Apr 14;6(4). pii: e004877. doi: 10.1161/JAHA.116.004877.</citation>
    <PMID>28411244</PMID>
  </reference>
  <reference>
    <citation>de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. Anticancer Drugs. 2014 May;25(5):488-94. doi: 10.1097/CAD.0000000000000093. Review. Erratum in: Anticancer Drugs. 2015 Feb;26(2):240.</citation>
    <PMID>24637579</PMID>
  </reference>
  <reference>
    <citation>Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Eur J Clin Invest. 2015 Mar;45(3):333-45. doi: 10.1111/eci.12407. Epub 2015 Feb 14. Review.</citation>
    <PMID>25615282</PMID>
  </reference>
  <reference>
    <citation>Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011 May;22(5):603-10. doi: 10.1016/j.jvir.2010.12.027. Epub 2011 Mar 17.</citation>
    <PMID>21419649</PMID>
  </reference>
  <reference>
    <citation>Banerjee S, Sarode K, Mohammad A, Gigliotti O, Baig MS, Tsai S, Shammas NW, Prasad A, Abu-Fadel M, Klein A, Armstrong EJ, Jeon-Slaughter H, Brilakis ES, Bhatt DL. Femoropopliteal Artery Stent Thrombosis: Report From the Excellence in Peripheral Artery Disease Registry. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730. doi: 10.1161/CIRCINTERVENTIONS.115.002730. Erratum in: Circ Cardiovasc Interv. 2016 Oct;9(10 ):.</citation>
    <PMID>26839391</PMID>
  </reference>
  <reference>
    <citation>Federman DG, Ladiiznski B, Dardik A, Kelly M, Shapshak D, Ueno CM, Mostow EN, Richmond NA, Hopf HW. Wound Healing Society 2014 update on guidelines for arterial ulcers. Wound Repair Regen. 2016 Jan-Feb;24(1):127-35. doi: 10.1111/wrr.12395. Review.</citation>
    <PMID>26663663</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

